OpGen, Inc. (NASDAQ:OPGN)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Monday. They currently have a $1.00 target price on the medical research company’s stock. HC Wainwright’s price target would suggest a potential upside of 212.60% from the stock’s current price.
A number of other brokerages have also weighed in on OPGN. Dawson James reaffirmed a “buy” rating on shares of OpGen in a report on Monday, June 19th. Zacks Investment Research raised OpGen from a “sell” rating to a “hold” rating in a report on Wednesday, June 28th.
OpGen (NASDAQ:OPGN) opened at 0.3299 on Monday. OpGen has a one year low of $0.30 and a one year high of $3.10. The stock has a 50 day moving average price of $0.32 and a 200 day moving average price of $0.93. The firm’s market cap is $17.01 million.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2887583/opgen-inc-opgn-given-a-1-00-price-target-by-hc-wainwright-analysts.html.
In other OpGen news, Chairman Jven Capital, Llc acquired 1,875,000 shares of the stock in a transaction on Tuesday, July 18th. The shares were bought at an average price of $0.40 per share, with a total value of $750,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Timothy C. Dec acquired 65,000 shares of the stock in a transaction on Tuesday, July 18th. The stock was acquired at an average cost of $0.40 per share, for a total transaction of $26,000.00. Following the acquisition, the chief financial officer now directly owns 118,966 shares in the company, valued at approximately $47,586.40. The disclosure for this purchase can be found here. 53.27% of the stock is currently owned by insiders.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. raised its holdings in OpGen, Inc. (NASDAQ:OPGN) by 1.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the quarter. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 as of its most recent filing with the Securities and Exchange Commission. 8.13% of the stock is currently owned by institutional investors and hedge funds.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.